Since the Trump administration's April 28 rescheduling order moved state-licensed medical marijuana from Schedule I to Schedule III, multi-state operators have been sprinting toward a DEA registration portal with the urgency of a closing bell. Trulieve filed for more than 200 dispensaries the day after the rule published. Verano followed in May. Jushi submitted applications on May 28 - the same day a federal court received what may be the most legally detailed challenge yet seeking to vacate the entire framework. What none of the accompanying press releases acknowledged is that the DEA's own application now asks operators whether they previously manufactured, distributed, or dispensed controlled substances without federal authorization. For most of the state cannabis industry, the honest answer is yes.
The 60-day application window - running until approximately June 27, 2026 - offers priority review, a six-month processing target, and a safe harbor provision allowing operators to continue running under state licenses while DEA considers their applications. Miss it, and that guaranteed continuity disappears. So operators across the country are moving fast, from large vertically integrated MSOs down to single-state licensees who rely on tools like marijuana pos software maryland to maintain compliant seed-to-sale tracking while federal rules continue to shift beneath them. The operational pressure is real. But the legal foundation these applications rest on is actively contested before a federal appeals court - and that gap between urgency and certainty is exactly where the compliance risk lives.
The Question Nobody in the Press Releases Answered
The DEA's binding Final Rule published in 2020 stated plainly that many state cannabis operators spent years manufacturing marijuana without DEA authorization in violation of federal law - and that prior compliance with federal law would receive "particular emphasis" in registration decisions. That language is still on the books. It did not disappear when the rescheduling order published. The expedited Schedule III pathway creates a new door, but it does not expunge a decade of operating outside the federal system.
MMJ International Holdings - which holds an active DEA Schedule I laboratory registration, spent more than eight years pursuing the FDA pharmaceutical pathway, and is now among the petitioners challenging the rescheduling order in the D.C. Circuit - has been direct about the contradiction. CEO Duane Boise put it plainly: "DEA told cannabis companies federal compliance mattered. Now the companies that ignored the rules want fast entry into the same federal system." That's not a fringe position. It is a live legal argument before a federal court, and it maps directly onto the question every applicant is answering on that DEA form right now.
Three Consolidated Petitions and a Hearing That May Be Unconstitutional
AG Order No. 6754-2026 - the rescheduling order itself - is the legal foundation for every DEA application being submitted under the expedited process. It is also the subject of three consolidated petitions for review in the U.S. Court of Appeals for the D.C. Circuit, filed May 4, May 22, and May 28. All three coalitions seek a stay, a declaration of unlawfulness, and vacatur of the order in its entirety.
The 13 grounds for challenge include arguments that the order exceeds the Attorney General's statutory authority, violates the APA's notice-and-comment requirements, contravenes the major questions doctrine, and was issued under an administrative law judge structure the DOJ itself has already conceded is unconstitutional. That last argument is particularly pointed: the same unconstitutional ALJ structure is scheduled to conduct the expedited rescheduling hearing beginning June 29. If the D.C. Circuit grants a stay before or during that hearing, the order is suspended, cannabis reverts to Schedule I, and every operator running under interim safe harbor status finds that status evaporated. The Congressional Research Service has already noted that the rescheduling order does not immediately bring state-licensed operators into federal compliance. That's not fringe analysis; that's the federal government's own research arm.
280E Relief, DEA Registrations, and the Risks Operators Are Not Being Told
The downstream benefits the industry is currently pricing in are each contingent on the order surviving judicial review. The 280E tax relief - which eliminates the prohibition on deductions that has long crushed dispensary margins - exists only because the order has not been stayed. Operators who have restructured their tax positions, taken deductions, or filed amended returns on the assumption that Schedule III is permanent carry real exposure. The IRS has issued no formal safe harbor guidance. A stay restores Schedule I status immediately; 280E snaps back with it.
The DEA registrations being filed right now are being filed into a live legal controversy. An operator who receives registration while a stay motion is pending does not receive a guarantee of anything. The registration is only as durable as the order that authorizes it. And operators being advised to file before the June 27 deadline to lock in safe harbor and priority review are often not being told that the entire legal basis for that safe harbor is before a federal appeals court whose ruling could retroactively eliminate it. The urgency is real. The certainty is not.
A Parallel Safety Problem the Industry Has Not Solved
Running beneath the rescheduling fight is a product safety problem that regulators and the industry have jointly treated as background noise. Less than 1% of cannabis research has focused on microbial contamination, according to peer-reviewed findings cited by MMJ in materials published as the legal challenges mounted; approximately 0.5% has examined pathogens, mycotoxins, and spoilage organisms. California - operating the most mature state cannabis market in the country - issued 63 recalls and 481 product embargoes in 2024 alone. Multiple state-licensed cannabis testing laboratories have faced enforcement actions involving allegations of potency inflation, data manipulation, and failures to identify contaminants.
The rescheduling order places state-licensed marijuana into Schedule III - a schedule historically reserved for drugs that have undergone FDA review. Not one marijuana product dispensed under a state license has received FDA approval. The petitioners argue there is no body of well-controlled scientific studies demonstrating that cannabis as sold in state dispensaries can effectively treat any specific medical condition at the level of rigor historically required for CSA scheduling. The order does not dispute this. It simply proceeds anyway. Meanwhile, a separate CMS program - the Substance Access Beneficiary Engagement Incentive, launched April 1, 2026 - has been distributing hemp-derived cannabinoid products to Medicare beneficiaries under ACO REACH and the Enhancing Oncology Model, with no FDA drug approval required. The European Food Safety Authority issued a scientific opinion in March 2026 concluding that the safety of a major hemp extract product could not be established, citing incomplete toxicology data. Europe said it doesn't know if the product is safe. The United States responded by having CMS distribute it to seniors.
For operators building compliance programs, maintaining COA documentation, investing in inventory tracking, and managing state testing requirements, the gap between what the regulatory environment demands in practice and what the federal government is actually doing at the policy level has rarely been wider. Filing a DEA application is not the same as being in federal compliance. And for the industry as a whole, the door that opened on April 28 may not stay open as long as the press releases suggest.
